Core Viewpoint - Tianpu Co., Ltd. announced that its stock trading suspension for verification has been completed, and trading will resume on September 18, 2025, after experiencing significant price fluctuations and multiple trading halts due to abnormal trading conditions [1][4]. Group 1: Stock Trading and Market Activity - The company's stock price experienced a continuous rise, hitting the upper limit for 11 consecutive trading days from August 22 to September 10, 2025 [1]. - The stock was previously suspended for verification due to abnormal trading activities, with the first suspension occurring from September 3 to September 9, 2025, after a similar price surge [4][5]. - As of September 17, 2025, the company's total market capitalization is 10.2 billion [2]. Group 2: Control Change and Acquisition - The company is in the process of a control change, with the acquirer planning to obtain control through agreement transfer and capital increase, with Yang Gongyifan set to become the new actual controller [3]. - The acquirer, Zhonghao Xinying (Hangzhou) Technology Co., Ltd., has no plans for asset injection or significant business changes within the next 12 months [3]. - As of September 15, 2025, the acquisition funds from Zhonghao Xinying amount to 9.65 billion, while another party, Fang Donghui, has contributed 7.64 billion, with partial funds from Hainan Chip Fan expected to be completed by September 19, 2025 [5]. Group 3: Insider Trading Investigation - There were rumors of insider information leakage related to the trading activities, but the company conducted a self-examination and found no evidence of insider trading, as the transactions occurred before the insider information was formed or known [4]. - Four individuals, identified as insiders, have returned their trading profits to Tianpu Co., Ltd. as of September 17, 2025 [4].

中信建投证券股份有限公司 关于宁波市天普橡胶科技股份有限公司控制权变更 有关事项的监管工作函回复的核查意见 上海证券交易所： 中信建投证券股份有限公司（以下简称"中信建投证券"、"财务顾问"）接受 中昊芯英（杭州）科技有限公司的委托，担任宁波市天普橡胶科技股份有限公司 控制权变更收购方的财务顾问。财务顾问根据贵所下发的《关于宁波市天普橡胶 科技股份有限公司控制权变更有关事项的监管工作函》（上证公函【2025】1272 号，以下简称"《监管工作函》"）要求，会同公司针对《监管工作函》进行了认 真讨论充分核查，现向贵所提交《监管工作函》回复的核查意见。 问题 1、关于收购目的 上市公司主营汽车用高分子流体管路系统及密封系统零件及总成，杨龚轶凡 控制的主要主体中昊芯英（杭州）科技有限公司（以下简称中昊芯英）主营 AI 芯片的设计、销售及提供算力解决方案，双方业务存在较大差异。此外，公司为 2020 年 8 月上市公司，自上市以来公司营业收入规模维持在 3 亿元，2025 年一 季度营业收入与归母净利润出现同比下滑。 请公司及相关方核实并说明：（1）公司原实控人尤建义让渡控制权的主要原 因及考虑，杨龚轶凡取得公司控制 ...

中信建投证券股份有限公司 关于宁波市天普橡胶科技股份有限公司 详式权益变动报告书 之 财务顾问核查意见 （修订稿） 二〇二五年九月 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益 变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市 公司收购报告书》及相关法律、法规的规定，中信建投证券股份有限公司（以 下简称"本财务顾问"或"中信建投证券"）按照证券行业公认的业务标准、 道德规范和勤勉尽责精神，就本次信息披露义务人及其一致行动人披露的《详 式权益变动报告书》进行核查，并出具核查意见。 2、本财务顾问所依据的有关资料由信息披露义务人提供。信息披露义务人 及其一致行动人已做出声明，保证其所提供的所有文件、材料及口头证言真实、 准确、完整、及时，副本资料或复印件与其原始资料或原件一致，所有文件的 签名、印章均是真实的，不存在任何重大遗漏、虚假记载或误导性陈述，并对 其真实性、准确性、完整性和合法性负责。 3、本财务顾问未委托和授权任何其他机构和个人提供未在本财务顾问核查 意见中列载的信息和对本财务顾问 ...

Group 1: Trading Suspension and Resumption - Tianpu Co., Ltd. has completed the stock trading suspension verification work and will resume trading tomorrow [1] - Pinming Technology is planning a significant matter that may lead to a change in company control, resulting in stock suspension [1] Group 2: Share Buybacks and Equity Transfers - Shuo Beid has proposed to adjust the upper limit of the share buyback price from 19.50 yuan per share to 30.00 yuan per share [2] - Shareholder SCPE of Aidi Te intends to transfer 3% of its equity through an inquiry [2] Group 3: External Investments and Daily Operations - Maiwei Bio has signed an exclusive licensing agreement with Kalexo, potentially receiving up to 1 billion USD in upfront and milestone payments [3] - Xingye Technology has signed a strategic cooperation agreement with Suzhou Nengsida to jointly develop flexible electronic skin [4] - Anke Bio's investee company PA3-17 injection has been approved to enter a critical Phase II clinical trial, being the first targeted CD7 autologous CAR-T cell therapy product to receive clinical trial approval globally [4] - Xujiahui has adjusted the Shanghai Liubai urban renewal project, with a planned total investment of approximately 1.698 billion yuan and an estimated construction period of 30-36 months [4] - Heng Rui Pharmaceutical's application for a new indication of injection Rituximab for breast cancer patients has been accepted and included in the priority review; drug HRS-5635 injection has been listed as a proposed breakthrough therapy [4] - Changhua Group has received a designated development notification from a domestic car manufacturer, with a total lifecycle sales amount of approximately 280 million yuan, expected to gradually start mass production in Q1 2027 [4] - Lvtong Technology has signed a strategic cooperation framework agreement with a subsidiary of Greeenmei Holdings for collaboration [5] - Runjian Co., Ltd. plans to issue debt financing instruments not exceeding 6 billion yuan to meet funding needs for computing power and other business [6] - Zhifei Biological's innovative drug CA111 injection has been approved to conduct clinical trials in overweight or obese adult patients [7] - Huahai Pharmaceutical's subsidiary has received FDA approval to conduct Phase I clinical trials for injection HB0043 [8] - Seli Medical plans to increase investment in Wuhan Huajiyuan by 42.74 million yuan to advance the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project through various clinical trial phases [8] - Changchun Gaoxin's subsidiary Jin Sai Pharmaceutical has paid 32.7 million euros to obtain exclusive rights to three ALK products in mainland China [9] - Greeenmei has signed a memorandum of understanding with ASCEND ELEMENTS to explore battery recycling and material cooperation in Europe [10]

天普股份（605255）(605255.SH)发布公告，近期，公司就股票交易异常波动及严重异常波动的相关事 项进行了核查。鉴于相关核查工作已完成，经公司向上海证券交易所申请，公司股票将于2025年9月18 日(星期四)开市起复牌。 市场传言，中昊芯英(杭州)科技有限公司将对公司注入资产。经公司自查，截至本公告日，收购方中昊 芯英无资产注入计划，中昊芯英自身现有资本证券化路径亦与本次收购上市公司无关。 ...

市场传言，中昊芯英(杭州)科技有限公司将对公司注入资产。经公司自查，截至本公告日，收购方中昊 芯英无资产注入计划，中昊芯英自身现有资本证券化路径亦与本次收购上市公司无关。 智通财经APP讯，天普股份(605255.SH)发布公告，近期，公司就股票交易异常波动及严重异常波动的 相关事项进行了核查。鉴于相关核查工作已完成，经公司向上海证券交易所申请，公司股票将于2025年 9月18日(星期四)开市起复牌。 ...

格隆汇9月17日丨天普股份(605255.SH)公布，近期，公司就股票交易异常波动及严重异常波动的相关事 项进行了核查。鉴于相关核查工作已完成，经公司向上海证券交易所申请，公司股票将于2025年9月18 日（星期四）开市起复牌。 市场传言，中昊芯英（杭州）科技有限公司将对公司注入资产。经公司自查，截至本公告日，收购方中 昊芯英无资产注入计划，中昊芯英自身现有资本证券化路径亦与本次收购上市公司无关。中昊芯英（杭 州）科技有限公司没有在未来12个月内改变上市公司主营业务或者对上市公司主营业务做出重大调整的 明确计划；没有在未来12个月内对上市公司及其子公司的资产和业务进行出售、合并、与他人合资或合 作的明确计划，或上市公司拟购买或置换资产的明确重组计划；及中昊芯英自身现有资本证券化路径亦 与本次收购无关。 ...

天普股份表示，经公司自查，四名内幕信息知情人在2025年2月14日至2025年8月14日期间存在买卖公司 股票行为。公司本次控制权变更事项不存在内幕信息提前泄露的情形，上述人员的股票交易行为均发生 在内幕信息形成或知悉之前，上述交易不属于内幕交易。截至2025年9月17日，四名自然人均已将买卖 公司股票所获收益上缴至天普股份。 对于公司目前筹划的控制权变更事项，天普股份表示，收购方中昊芯英无资产注入计划，中昊芯英自身 现有资本证券化路径亦与本次收购上市公司无关。另外，截至2025年9月17日，收购方之一海南芯繁企 业管理合伙企业（有限合伙）收购资金3.95亿元已完成实缴。 北京商报讯（记者 马换换 王蔓蕾）9月17日晚间，天普股份（605255）披露公告称，近期，公司就股票 交易异常波动及严重异常波动的相关事项进行了核查。鉴于相关核查工作已完成，公司股票将于9月18 日开市起复牌。 据悉，天普股份股票价格2025年8月22日至2025年9月10日连续11个交易日涨停，累计上涨185.29%，同 期上证指数累计上涨3.98%，同期汽车零部件行业指数累计上涨5.9%，公司股价短期涨幅严重偏离同期 上证指数和汽车零 ...

证券代码：605255 证券简称：天普股份 公告编号：2025-045 宁波市天普橡胶科技股份有限公司 关于股票交易停牌核查结果暨复牌的公告 | 证券代码 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 605255 | 天普股份 | A 股 | 复牌 | | | 2025/9/17 | 2025/9/18 | 根据《上海证券交易所上市公司自律监管指引第 4 号——停复牌》《上海证券 交易所股票上市规则》等相关规定，经向上海证券交易所申请，本公司股票于 2025 年 9 月 18 日（星期四）开市起复牌。 ● 公司股票于 2025 年 8 月 22 日至 9 月 10 日连续 11 个交易日涨停，短期涨 幅与同期上证指数、汽车零部件行业指数存在严重偏离。为维护投资者利益，公 司就股票交易情况进行了核查。公司郑重提醒广大投资者，公司股价可能存在短 期涨幅较大后下跌的风险，请投资者务必充分了解二级市场交易风险，切实提高 风险意识，理性决策、审慎投资。 ● 四名自 ...

Core Viewpoint - The company will resume trading on September 18, 2025, after a significant stock price increase of 185.29% over 11 consecutive trading days from August 22 to September 10, 2025 [1] Company Performance - In the first half of 2025, the company reported revenue of 151 million yuan, a year-on-year decrease of 3.44% [1] - The net profit attributable to shareholders was 11.298 million yuan, reflecting a year-on-year decline of 16.08% [1] Stock Trading and Risks - The stock price has significantly deviated from the Shanghai Composite Index and the automotive parts industry index, indicating potential for a rapid decline [1] - There is uncertainty regarding the change in company control, which may affect compliance with listing conditions due to the distribution of shares [1] - The acquisition plan by Zhonghao Xinying lacks asset injection, and there is a risk of transaction termination [1]